23 of Aalto Startup Center ecosystem’s startups are attending the Arctic15 event. Arctic15 is a Startup Investor Event and a meeting spot for startup entrepreneurs, investors, corporates and media from 60+ countries.
What kind of team do you have at the moment?
RoboMed: RoboMed Oy has an experienced and motivated team of 7 industrial and academic experts working full-time and four other members working part-time. The team was founded in early 2019 and the corporation (RoboMed Oy) was established in September 2020.
What is your innovation?
RoboMed: RoboMed’s solution is directed to the need of non-invasive solutions for the biopsy of the intestine with a robotic capsule. A non-invasive solution which avoids the traditional method’s various side effects of surgery, wound, anesthesia, and radiation. In RoboMed’s solution, a pill-sized robot is swallowed by the patient and performs biopsy and endoscopy simultaneously for diagnosis and prevention of intestine disease, disorders, and cancers. Our primary customers are hospitals, clinics, medical centers, endoscopy centers and internal organ specialists to use this for prospective patients.
RoboMed helps with the diagnosis and detection of various diseases such as Crohn’s Disease, Celiac Disease, Ulcerative Colitis, Inflammatory Bowel Disease, colorectal cancer and tumors. Early diagnosis and detection will reduce medical costs for treating before it reaches the critical stage and prevent it. This is going to help to indicate and identify suspected patients at the early stages of the disease before it becomes progressed and serious.
What is your impact in society?
RoboMed: The primary impact is saving human lives, alternative and applicable solutions for the medical doctors, non-invasive solution availability for the patients and a more diagnosed society are achievable. Added to this cheaper and lower price of diagnostics availability make it more popular and affordable to the society.
What is your impact in users and customers?
RoboMed: It’s a non-invasive solution with a simple and user-friendly procedure for the users while the side effects are minimised. It avoids various side effects in a pleasant way for the prediction and prevention of the gastrointestinal tract.
What are your main Sustainable Development Goals and why?
RoboMed: Our main vision and mission is to save lives, help human beings live safer and healthier by bringing advanced technologies into medical devices. This is targeting SDG 3 Good Health and Well-Being* for promoting well-being to humans and ensuring healthy lives.
*Source: United Nations: sdgs.un.org/goals
How will people’s lives change with your innovation?
RoboMed: A life could be saved, diseases could be prevented, a symptom shall be predicted by monitoring and sampling of the small intestine, one of the most inaccessible organs of the human body.
What are your next steps?
RoboMed: RoboMed is in the process of ISO13485, QMS establishment, and clinical trials to apply for a CE certificate aimed at Nordic countries and the whole EU in the first phase. Their innovation is patented, the first prototype is already launched and they have ongoing negotiations for supply chain and custom-based equipment. The next phase would be ASEAN countries and the Middle East.
Read more:
Website: robomed.fi
LinkedIn: linkedin.com/company/robomedltd